These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7738926)

  • 21. Ovarian estradiol production in vivo. Inhibitory effect of leuprolide acetate.
    Kowalik A; Barmat L; Damario M; Liu HC; Davis O; Rosenwaks Z
    J Reprod Med; 1998 May; 43(5):413-7. PubMed ID: 9610463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Lovelace Health Systems chronic pelvic pain protocol.
    Kephart W
    Am J Manag Care; 1999 May; 5(5 Suppl):S309-15. PubMed ID: 10537663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development.
    Lainas TG; Petsas GK; Zorzovilis IZ; Iliadis GS; Lainas GT; Cazlaris HE; Kolibianakis EM
    Hum Reprod; 2007 Jun; 22(6):1540-6. PubMed ID: 17347165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
    Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact.
    Qublan HS; Amarin Z; Tahat YA; Smadi AZ; Kilani M
    Hum Reprod; 2006 Mar; 21(3):640-4. PubMed ID: 16253965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Application of gonadotropin-releasing hormone agonist for triggering ovulation in high risk gonadotropin stimulating cycles of infertile polycystic ovary syndrome patients].
    Dong H; Chen S; Xing F
    Zhonghua Fu Chan Ke Za Zhi; 1999 Feb; 34(2):94-6. PubMed ID: 11263206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian remnant syndrome: diagnostic dilemma and surgical challenge.
    Pettit PD; Lee RA
    Obstet Gynecol; 1988 Apr; 71(4):580-3. PubMed ID: 3281076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometriosis in the ovary.
    Maitoko K; Sasaki H
    Fertil Steril; 2004 Aug; 82(2):322-6. PubMed ID: 15302278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian remnant syndrome: revascularization of free-floating ovarian tissue in the feline abdominal cavity.
    DeNardo GA; Becker K; Brown NO; Dobbins S
    J Am Anim Hosp Assoc; 2001; 37(3):290-6. PubMed ID: 11361123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian remnant syndrome: experience at Jackson Memorial Hospital, University of Miami, 1985 through 1993.
    Lafferty HW; Angioli R; Rudolph J; Penalver MA
    Am J Obstet Gynecol; 1996 Feb; 174(2):641-5. PubMed ID: 8623799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian remnant syndrome.
    Symmonds RE; Pettit PD
    Obstet Gynecol; 1979 Aug; 54(2):174-7. PubMed ID: 460750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian remnant syndrome.
    Steege JF
    Obstet Gynecol; 1987 Jul; 70(1):64-7. PubMed ID: 3110713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of laparoscopic surgical treatment of ovarian remnant and ovarian retention syndromes.
    Martinez A; Howard FM
    J Minim Invasive Gynecol; 2015 Feb; 22(2):245-9. PubMed ID: 25460318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ovarian remnant syndrome. Apropos of 4 cases].
    Bouquet de Jolinière J; de Brux J; Senèze J; Ulman D
    Rev Fr Gynecol Obstet; 1986; 81(6-7):333-9. PubMed ID: 3764293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian residual syndrome.
    Bukovsky I; Liftshitz Y; Langer R; Weinraub Z; Sadovsky G; Caspi E
    Surg Gynecol Obstet; 1988 Aug; 167(2):132-4. PubMed ID: 3400031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.